This work aims to propose a Quantum-Classical Neural Network with Variational quantum circuit (QCNN-VQC) to improve the accuracy of molecular docking in drug discovery. The model combines the classical feature extraction framework with quantum representations and energy-based optimisation to simulate intricate protein-ligand interactions. The molecular features are initially encoded into quantum states by first a standard neural network and then by encoding them into quantum states, where non-linear correlations and entanglement effects are modeled by variational circuits. An optimization strategy is used, that is quantum-inspired to achieve the minimum docking energy and find stable binding conformations. The experimental analysis of molecular docking datasets reveals that the proposed model achieves an accuracy of 91.2% compared to the classical neural networks (78.5%), and deep learning models (82.3%). The model also has a lower RMSE of 0.38 and higher R2score of 0.89 which means that it predicts better. The results of energy minimization indicate that the docking energy is greatly reduced, which proves the increased binding stability. The hybrid model is slightly more expensive to compute but it has competitive inference time. In general, QCNN VQC architecture offers a scalable and efficient drug discovery system; it can be optimally applied to quantum optimization in conjunction with deep learning and can result in a better prediction and strong molecular interaction modeling.
This work aims to propose a Quantum-Classical Neural Network with Variational quantum circuit (QCNN-VQC) to improve the accuracy of molecular docking in drug discovery. The model combines the classical feature extraction framework with quantum representations and energy-based optimisation to simulate intricate protein-ligand interactions. The molecular features are initially encoded into quantum states by first a standard neural network and then by encoding them into quantum states, where non-linear correlations and entanglement effects are modeled by variational circuits. An optimization strategy is used, that is quantum-inspired to achieve the minimum docking energy and find stable binding conformations. The experimental analysis of molecular docking datasets reveals that the proposed model achieves an accuracy of 91.2% compared to the classical neural networks (78.5%), and deep learning models (82.3%). The model also has a lower RMSE of 0.38 and higher R2score of 0.89 which means that it predicts better. The results of energy minimization indicate that the docking energy is greatly reduced, which proves the increased binding stability. The hybrid model is slightly more expensive to compute but it has competitive inference time. In general, QCNN VQC architecture offers a scalable and efficient drug discovery system; it can be optimally applied to quantum optimization in conjunction with deep learning and can result in a better prediction and strong molecular interaction modeling.
Accurate prediction of binding affinities and efficient lead optimization remain central challenges in computational drug discovery, particularly for complex biological targets characterized by rugged energy landscapes, conformational heterogeneity, and high-dimensional interaction spaces. Classical computational methods—such as molecular docking, force-field–based simulations, and deep learning models—have made substantial progress, yet they often struggle to capture quantum-mechanical effects and long-range correlations critical to molecular recognition. This study explores a quantum-enhanced framework that integrates Variational Quantum Algorithms (VQAs), quantum-inspired Hamiltonian modeling, and hybrid quantum–classical optimization workflows to improve the fidelity and scalability of drug discovery pipelines. By encoding molecular interactions into parameterized quantum circuits, the framework leverages quantum superposition and entanglement to explore complex chemical space more efficiently, enabling refined estimation of binding energies and accelerated identification of high-quality leads. Preliminary simulations indicate that VQA-based estimators outperform classical baselines for challenging protein–ligand systems, reducing prediction error while maintaining computational tractability. These findings highlight the emerging potential of quantum technologies to enable more accurate, data-efficient, and mechanistically grounded drug discovery for next-generation therapeutics.
Drug discovery hinges on the accurate prediction of binding affinity between prospective drug molecules and target proteins that influence disease progression, which is financially and computationally demanding. Although classical and hybrid quantum machine learning models have been employed in previous studies to aid in binding affinity prediction, they encounter several issues related to convergence stability and prediction accuracy. In this regard, this paper introduces a novel hybrid quantum-classical deep learning model tailored for binding affinity prediction in drug discovery. Specifically, the proposed model synergistically integrates 3D and spatial graph convolutional neural networks within an optimized quantum circuit architecture. Simulation results demonstrate a 6% improvement in prediction accuracy relative to existing classical models, as well as a significantly more stable convergence performance compared to previous classical approaches. Moreover, to scalably deploy the proposed framework over today's noisy intermediate-scale quantum (NISQ) devices, a novel quantum error mitigation algorithm is proposed. This algorithm outperforms existing techniques and is capable of mitigating errors with gate noise probabilities,p≤0.05, while resulting in no additional overhead during the training and testing phases.
Regenerative medicine requires rapid analysis of the best therapeutic molecules capable of interacting with in vivo undifferentiated mass with complex biology and therapeutic properties that are needed to repair and regenerate tissues. The scalability and efficiency of conventional computational solutions and even recent representations with more advanced classical neural networks are limited when it comes to molecular data that are high dimensional. The combination of quantum computing principles and deep learning neural networks provides a potential avenue to speed this process up, by exploiting quantum parallelism, entanglement and superposition in pattern recognition and simulation of molecules through what is known as Quantum Neural Networks (QNNs). The paper describes how to apply QNNs to facilitate the process of target identification, molecular docking, and compound optimization in regenerative medicine in particular. We introduce a conceptual, hybrid quantum classical model to simulate protein-ligand interactions, screen drug candidates and economize on computational costs relative to classical models. The offered solution marks the conceivably quicker performance in molecular screening, better sensitivity in predicting drug-target interactions, and accommodating complex biological data. QNNs by connecting both quantum computing and biomedical innovation can foreseeably lead to much shorter time-to-discovery, yielding more successfully and personified regenerative treatments.
Drug repositioning is a less expensive and time-consuming method than the traditional method of drug discovery. It is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. A key strategy in repositioning approved or investigational drugs is determining the binding affinity of these drugs to target proteins. The large increase in available experimental data has helped deep learning methods to demonstrate superior performance compared to conventional prediction and other traditional computational methods in precise binding affinity prediction. However, these methods are complex and time-consuming, presenting a significant barrier to their development and practical application. In this context, quantum computing (QC) and quantum machine learning (QML) theoretically offer promising solutions to effectively address these challenges. In this work, we introduce a hybrid quantum–classical framework to predict binding affinity. Our approach involves, initially, the implementation of an efficient classical model using convolutional neural networks (CNNs) for feature extraction and three fully connected layers for prediction. Subsequently, retaining the classical module for feature extraction, we implement various quantum and classical modules for binding affinity prediction, which accept the concatenated features as input. Quantum predicted modules are implemented with Variational Quantum Regressions (VQRs), while classical predicted modules are implemented with various fully connected layers. Our findings clearly show that hybrid quantum–classical models accelerate the training process in terms of epochs and achieve faster stabilization. Also, these models demonstrate quantum superiority in terms of complexity, accuracy, and generalization, thereby indicating a promising direction for QML.
The pharmaceutical industry faces mounting challenges in drug discovery, where exploring a chemical space exceeding 10 60 possible compounds remains computationally prohibitive. Traditional in-silico screening approaches struggle to capture the quantum mechanical interactions that determine molecular behavior. To overcome these limitations, this study introduces a hybrid quantum–classical machine learning framework that uniquely integrates molecular graph theory with quantum-enhanced learning for accelerated drug discovery. Using the QM9 benchmark dataset containing 133,885 molecules of low-to-medium structural complexity, we extract Laplacian eigenvalue spectra as topological descriptors that preserve both connectivity and electronic information. These features are jointly processed by Random Forest (RF), Support Vector Machine (SVM), and a Variational Quantum Classifier (VQC) in a weighted ensemble architecture designed for balanced generalization. The Quantum Graph Neural Network (QGNN) component achieves 97.5% accuracy, while the hybrid ensemble attains 100.0% accuracy, confirming strong predictive reliability. Although quantum training requires roughly 3.2× longer computation, it captures high-dimensional correlations that classical methods overlook. Overall, the proposed framework bridges the gap between theoretical quantum computing and practical pharmaceutical modeling, providing a scalable, physics-inspired pathway toward intelligent molecular screening and next-generation drug discovery systems.
Recent advances in quantum machine learning (QML) have opened new pathways for accelerating early-stage drug discovery through molecular representation in Hilbert space [1]–[3]. In this work, we present a hybrid quantum–classical framework that integrates quantum kernel estimation and variational quantum neural networks (QNNs) for ligand–target binding prediction [4], [5].A synthetic dataset reflecting the statistical behavior of the BindingDB database [6] was constructed to evaluate quantum descriptors and kernel performance under controlled conditions. The proposed quantum feature maps translate seven key molecular descriptors—molecular weight (MW), logP, hydrogen bond donors (HBD), acceptors (HBA), rotatable bonds (RB), aromatic rings (AR), and topological polar surface area (TPSA)—into entangled qubit states [7], [8].Comparative analyses with classical baselines (SVR, Random Forest, and deep neural networks) revealed that quantum embeddings achieve competitive predictive accuracy (RMSE ≈ 0.06) with improved stability under bootstrap resampling [9]. Quantum kernel alignment and sensitivity studies demonstrated that aromaticity and polarity jointly determine the representational power of QML models [10].Beyond performance, we emphasize Explainable Quantum Pharmacology (EQP)—a paradigm in which interpretability, reproducibility, and physicochemical causality are as essential as accuracy [11].Our findings establish a reproducible, interpretable, and computationally efficient foundation for hybrid QML pipelines in molecular modeling, paving the way for next-generation AI-driven drug discovery.